Antibacterial Resistance Leadership Group 2.0: Back to Business.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021 Aug 16

filter terms:

In December 2019, the Antibacterial Resistance Leadership Group (ARLG) was awarded funding for another 7-year cycle to support a clinical research network on antibacterial resistance. ARLG 2.0 has 3 overarching research priorities: infections caused by antibiotic-resistant (AR) gram-negative bacteria, infections caused by AR gram-positive bacteria, and diagnostic tests to optimize use of antibiotics. To support the next generation of AR researchers, the ARLG offers 3 mentoring opportunities: the ARLG Fellowship, Early Stage Investigator seed grants, and the Trialists in Training Program. The purpose of this article is to update the scientific community on the progress made in the original funding period and to encourage submission of clinical research that addresses 1 or more of the research priority areas of ARLG 2.0. © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Citation

Henry F Chambers, Scott R Evans, Robin Patel, Heather R Cross, Anthony D Harris, Yohei Doi, Helen W Boucher, David van Duin, Ephraim L Tsalik, Thomas L Holland, Melinda M Pettigrew, Pranita D Tamma, Kathryn R Hodges, Maria Souli, Vance G Fowler. Antibacterial Resistance Leadership Group 2.0: Back to Business. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 Aug 16;73(4):730-739